Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accounts Payables: 2009-2025

Historic Accounts Payables for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $13.8 million.

  • Cumberland Pharmaceuticals' Accounts Payables rose 14.72% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 14.72%. This contributed to the annual value of $13.9 million for FY2024, which is 0.88% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Accounts Payables of $13.8 million as of Q3 2025, which was up 2.87% from $13.4 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Accounts Payables ranged from a high of $14.0 million in Q4 2023 and a low of $9.0 million during Q2 2021.
  • In the last 3 years, Cumberland Pharmaceuticals' Accounts Payables had a median value of $13.1 million in 2024 and averaged $12.7 million.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Accounts Payables fell by 28.03% in 2021 and then climbed by 29.75% in 2023.
  • Cumberland Pharmaceuticals' Accounts Payables (Quarterly) stood at $9.6 million in 2021, then increased by 12.22% to $10.8 million in 2022, then rose by 29.75% to $14.0 million in 2023, then declined by 0.88% to $13.9 million in 2024, then grew by 14.72% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $13.4 million for Q2 2025, and $13.9 million during Q1 2025.